

NEW!

Senvelgo 

# Just what cats ordered

*A convenient, once-daily, oral solution for diabetes*



**Senvelgo®'s novel approach means you can now treat diabetes without injecting insulin**

- ◆ Simple dosing according to bodyweight
- ◆ Reduced risk of clinical hypoglycaemia
- ◆ Glycaemic control can be achieved within a week<sup>1,2</sup>

**Make Senvelgo® your new, simple solution for diabetic cats and their owners**



Scan to  
learn more



1. Niessen, S. J. M. et al. (2022) Once daily oral therapy for feline diabetes mellitus: evaluation of SGLT-2 inhibitor velagliflozin as stand-alone therapy compared to insulin injection therapy in diabetic cats. Journal of Veterinary Internal Medicine 36, 2512–2513.  
2. Sparkes, A. H. et al. (2015) ISFM Consensus Guidelines on the Practical Management of Diabetes Mellitus in Cats. J Feline Med Surg 17, 235–50.

Senvelgo® contains velagliflozin (sodium-glucose co-transporter 2 [SGLT-2] inhibitor). UK(NI): POM-V IE: POM. Further information available in the SPC or from Boehringer Ingelheim Animal Health UK Ltd., RG12 8YS, UK. UK(NI) Tel: 01344 746959 (sales) or 01344 746957 (technical), IE Tel: 01 291 3985 (all queries). Email: [vetenquiries@boehringer-ingelheim.com](mailto:vetenquiries@boehringer-ingelheim.com). Senvelgo® is a registered trademark of Boehringer Ingelheim Vetmedica GmbH, used under licence.  
©2024 Boehringer Ingelheim Animal Health UK Ltd. All rights reserved. Date of preparation: Feb 2024. UI-PET-0022-2024. Use Medicines Responsibly